Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 9,514 matching trials from the live ClinicalTrials.gov search.
Filters: Birmingham, Alabama Clear all
Completed Not applicable Interventional

Advanced Glycation End-products, Inflammation and Vascular Health in Chronic Kidney Disease

NCT01769963
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Research diet
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 1, 2014 · Synced Oct 20, 2026, 10:16 PM EDT
Recruiting Phase 3 Interventional

Effects of Oral Tranexamic Acid on Short Term Postoperative Outcomes Following Total Shoulder Arthroplasty

NCT06902714
View directory record Official record
Conditions
Shoulder Arthroplasty
Interventions
oral tranexamic acid, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 79 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 20, 2026, 10:16 PM EDT
Completed Phase 2 Interventional

Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder

NCT01868516
View directory record Official record
Conditions
Overactive Bladder
Interventions
dexmecamylamine, Placebo
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
125
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 109 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 20, 2026, 10:16 PM EDT
Completed Phase 3 Interventional

S9900: Surgery With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer

NCT00004011
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, conventional surgery
Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
267
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 197 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 20, 2026, 10:16 PM EDT
Active, not recruiting Phase 3 Interventional

A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

NCT06161571
View directory record Official record
Conditions
NASH/MASH, NAFLD/MASLD
Interventions
Efruxifermin, Placebo
Drug
Lead sponsor
Akero Therapeutics, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
139
States / cities
Birmingham, Alabama • Chandler, Arizona • Flagstaff, Arizona + 117 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 20, 2026, 10:16 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy

NCT03283371
View directory record Official record
Conditions
Epilepsy, Focal Seizures, Partial Seizures
Interventions
Natalizumab, Placebo
Drug · Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Oct 20, 2026, 10:16 PM EDT
Terminated Phase 1 Interventional

Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

NCT05511844
View directory record Official record
Conditions
HER2-positive Breast Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification, HER2 Gene Mutation
Interventions
ORM-5029
Drug
Lead sponsor
Orum Therapeutics USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 20, 2026, 10:16 PM EDT
Completed Phase 1 Interventional

Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes

NCT00028899
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
asparaginase, cytarabine, gemtuzumab ozogamicin, mitoxantrone hydrochloride
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
70
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2014 · Synced Oct 20, 2026, 10:16 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

NCT00251693
View directory record Official record
Conditions
Esophagitis, Reflux, Esophagitis, Peptic
Interventions
Dexlansoprazole MR, Lansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
2,038 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
96
States / cities
Alabaster, Alabama • Birmingham, Alabama • Huntsville, Alabama + 93 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 20, 2026, 10:16 PM EDT
Completed Phase 3 Interventional Results available

Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

NCT00981214
View directory record Official record
Conditions
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions
EUR-1008 (APT-1008)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
Up to 7 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 20, 2026, 10:16 PM EDT
Completed Not applicable Interventional

A Multisite Trial of ACQUIREc Therapy

NCT00991692
View directory record Official record
Conditions
Hemiparetic Cerebral Palsy
Interventions
Therapy services (ACQUIREc Therapy)
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
3 Years to 8 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 8, 2009 · Synced Oct 20, 2026, 10:16 PM EDT
Terminated Phase 1 Interventional

Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT04975399
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CC-92328
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 20, 2026, 10:16 PM EDT
Active, not recruiting Not applicable Interventional

DCM Precision Medicine Study

NCT03037632
View directory record Official record
Conditions
Idiopathic Dilated Cardiomyopathy
Interventions
Family Heart Talk Booklet
Behavioral
Lead sponsor
Ray Hershberger
Other
Eligibility
Not listed
Enrollment
6,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
26
States / cities
Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 20, 2026, 10:16 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Subcutaneous Mircera for the Treatment of Anemia in Peritoneal Dialysis Patients.

NCT00442416
View directory record Official record
Conditions
Anemia
Interventions
Epoetin alfa, methoxy polyethylene glycol-epoetin beta [Mircera]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
29
States / cities
Birmingham, Alabama • Bakersfield, California • Chula Vista, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2016 · Synced Oct 20, 2026, 10:16 PM EDT
Completed Phase 2 Interventional

External-Beam Radiation Therapy Plus Implanted Radiation Therapy in Treating Patients With Prostate Cancer

NCT00006365
View directory record Official record
Conditions
Prostate Cancer
Interventions
brachytherapy, iodine I 125, radiation therapy
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
236
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 184 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 20, 2026, 10:16 PM EDT
Completed Phase 3 Interventional Results available

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

NCT00066690
View directory record Official record
Conditions
Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
Interventions
Exemestane, Laboratory Biomarker Analysis, Oophorectomy, Quality-of-Life Assessment, Radiation Therapy, Tamoxifen, Triptorelin
Drug · Other · Procedure + 1 more
Lead sponsor
ETOP IBCSG Partners Foundation
Network
Eligibility
18 Years to 65 Years · Female only
Enrollment
3,066 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2024
U.S. locations
480
States / cities
Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 323 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 20, 2026, 10:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reimbursement Effects on Enrollment in Obesity Treatment

NCT00250510
View directory record Official record
Conditions
Obesity
Interventions
Simulated insurance reimbursement
Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
19 Years and older
Enrollment
401 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 18, 2010 · Synced Oct 20, 2026, 10:16 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Female Urine, Vaginal & Endocervical Swab & Cervical Specimen Collections for APTIMA Trichomonas Vaginalis Assay Testing

NCT01427023
View directory record Official record
Conditions
Trichomonas Vaginalis
Interventions
APTIMA Trichomonas vaginalis (ATV) Assay
Device
Lead sponsor
Gen-Probe, Incorporated
Industry
Eligibility
14 Years and older · Female only
Enrollment
532 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
7
States / cities
Birmingham, Alabama • Indianapolis, Indiana • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 20, 2026, 10:16 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers Results available

A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult Participants

NCT05217641
View directory record Official record
Conditions
HIV Infections
Interventions
BG505 MD39.3 mRNA, BG505 MD39.3 gp151 mRNA, BG505 MD39.3 gp151 CD4KO mRNA
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 20, 2026, 10:16 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT07363694
View directory record Official record
Conditions
Moderate to Severe Chronic Obstructive Pulmonary Disease
Interventions
PF-07275315 dose 1, PF-07275315-dose 2, Placebo, PF-07275315-dose 3
Drug
Lead sponsor
Pfizer
Industry
Eligibility
35 Years to 80 Years
Enrollment
1,156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
61
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 20, 2026, 10:16 PM EDT
Completed No phase listed Observational

Clinical Evaluation of Three Dental Adhesive Systems in Class V Restorations

NCT00643461
View directory record Official record
Conditions
Dental Caries
Interventions
Adhesive A, Adhesive B, Adhesive C
Device
Lead sponsor
Solventum US LLC
Industry
Eligibility
19 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 20, 2026, 10:16 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Aspirin in Reducing Events in the Elderly

NCT01038583
View directory record Official record
Conditions
Functional Disability, Dementia, Heart Disease, Stroke, Cancer, Bleeding, Depression
Interventions
100 mg enteric-coated aspirin, Placebo
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
65 Years and older
Enrollment
19,114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2024
U.S. locations
33
States / cities
Birmingham, Alabama • Palo Alto, California • Washington D.C., District of Columbia + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Oct 20, 2026, 10:16 PM EDT
Not listed No phase listed Observational

Safety of Oral Anticoagulants Registry

NCT02745054
View directory record Official record
Conditions
Blood Coagulation
Interventions
mgt of bleeding concerns/complications of oral anticoagulants
Other
Lead sponsor
Hospital Quality Foundation
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
9
States / cities
Birmingham, Alabama • Hartford, Connecticut • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 20, 2026, 10:16 PM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Safety of the Drugs Topiramate and Levetiracetam in Treating Children Recently Diagnosed With Epilepsy

NCT02201251
View directory record Official record
Conditions
Epilepsy
Interventions
Topiramate, Levetiracetam
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 15 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Gulf Breeze, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 20, 2026, 10:16 PM EDT